FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782140699> ?p ?o ?g. }

• W2782140699 endingPage "e0190509" @default.
• W2782140699 startingPage "e0190509" @default.
• W2782140699 abstract "Drug repositioning or repurposing, i.e. identifying new indications for existing drugs, has gained increasing attention in the recent years. This approach enables the scientists to discover “new targets” for known drugs in a cost and time efficient manner. Glycation, the non-enzymatic reaction of sugars with proteins or nucleic acids to form early glycation (Amadori or fructosamine) products, is a key molecular basis of diabetic complications. Inhibiting the process of non-enzymatic protein glycation is one of the key strategies to prevent glycation-mediated diabetic complications. The present study focuses on the anti-glycation activity of 18 drugs, commonly used for the treatment of gastrointestinal, central nervous system, inflammatory diseases, bacterial infections, and gout. This study was carried out by using two in-vitro protein anti-glycation assay models. Results revealed that nimesulide (3), a non-steroidal anti-inflammatory drug, possesses a good anti-glycation activity in in-vitro BSA-MG and BSA-glucose glycation models with IC50 values of 330.56 ± 2.90, and 145.46 ± 16.35 μM, respectively. Phloroglucinol dihydrate (11), a drug used for the treatment of gastrointestinal diseases, showed a weak activity in BSA-MG glycation model (IC50 = 654.89 ± 2.50 μM), while it showed a good activity in BSA-glucose assay (IC50 = 148.23 ± 0.15 μM). Trimethylphloroglucinol (9), a drug used for the treatment of pain related to functional disorders of the digestive and biliary tracts, also showed a good antiglycation activity in BSA-MG model (IC50 = 321.15 ± 1.26 μM), while it was found to be inactive in in-vitro BSA-glucose assay (IC50 = 12.95% inhibition). These activities of drugs were compared with the anti-glycation activity of the standard, rutin (IC50 = 294.5 ± 1.50 μM in BSA-MG glycation model, and IC50 = 86.94 ± 0.24 μM in BSA- glucose model). Rest of the drugs exhibited a relatively weak antiglycation activity. This study identifies nimesulide (3), and phloroglucinol dihydrate (11) as new inhibitors of in-vitro protein glycation for further investigations as potential anti-diabetic agents." @default.
• W2782140699 created "2018-01-12" @default.
• W2782140699 creator A5027563484 @default.
• W2782140699 creator A5040577138 @default.
• W2782140699 creator A5051561991 @default.
• W2782140699 creator A5053039896 @default.
• W2782140699 creator A5070441687 @default.
• W2782140699 date "2018-01-04" @default.
• W2782140699 modified "2023-10-15" @default.
• W2782140699 title "Drug repurposing: In-vitro anti-glycation properties of 18 common drugs" @default.
• W2782140699 cites W1968505616 @default.
• W2782140699 cites W1970198869 @default.
• W2782140699 cites W1985081974 @default.
• W2782140699 cites W1985143893 @default.
• W2782140699 cites W1985270532 @default.
• W2782140699 cites W2003531367 @default.
• W2782140699 cites W2019005560 @default.
• W2782140699 cites W2031860130 @default.
• W2782140699 cites W2036511281 @default.
• W2782140699 cites W2053769775 @default.
• W2782140699 cites W2066164553 @default.
• W2782140699 cites W2089324920 @default.
• W2782140699 cites W2102242005 @default.
• W2782140699 cites W2118987172 @default.
• W2782140699 cites W2124709546 @default.
• W2782140699 cites W2137952375 @default.
• W2782140699 cites W2138631692 @default.
• W2782140699 cites W2139923324 @default.
• W2782140699 cites W2145738090 @default.
• W2782140699 cites W2164146770 @default.
• W2782140699 cites W2174011260 @default.
• W2782140699 cites W2408773744 @default.
• W2782140699 doi "https://doi.org/10.1371/journal.pone.0190509" @default.
• W2782140699 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5754062" @default.
• W2782140699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29300762" @default.
• W2782140699 hasPublicationYear "2018" @default.
• W2782140699 type Work @default.
• W2782140699 sameAs 2782140699 @default.
• W2782140699 citedByCount "30" @default.
• W2782140699 countsByYear W27821406992018 @default.
• W2782140699 countsByYear W27821406992019 @default.
• W2782140699 countsByYear W27821406992020 @default.
• W2782140699 countsByYear W27821406992021 @default.
• W2782140699 countsByYear W27821406992022 @default.
• W2782140699 countsByYear W27821406992023 @default.
• W2782140699 crossrefType "journal-article" @default.
• W2782140699 hasAuthorship W2782140699A5027563484 @default.
• W2782140699 hasAuthorship W2782140699A5040577138 @default.
• W2782140699 hasAuthorship W2782140699A5051561991 @default.
• W2782140699 hasAuthorship W2782140699A5053039896 @default.
• W2782140699 hasAuthorship W2782140699A5070441687 @default.
• W2782140699 hasBestOaLocation W27821406991 @default.
• W2782140699 hasConcept C134018914 @default.
• W2782140699 hasConcept C147990577 @default.
• W2782140699 hasConcept C170493617 @default.
• W2782140699 hasConcept C185592680 @default.
• W2782140699 hasConcept C202751555 @default.
• W2782140699 hasConcept C2777752497 @default.
• W2782140699 hasConcept C2780035454 @default.
• W2782140699 hasConcept C2781357877 @default.
• W2782140699 hasConcept C55493867 @default.
• W2782140699 hasConcept C555293320 @default.
• W2782140699 hasConcept C71924100 @default.
• W2782140699 hasConcept C98274493 @default.
• W2782140699 hasConceptScore W2782140699C134018914 @default.
• W2782140699 hasConceptScore W2782140699C147990577 @default.
• W2782140699 hasConceptScore W2782140699C170493617 @default.
• W2782140699 hasConceptScore W2782140699C185592680 @default.
• W2782140699 hasConceptScore W2782140699C202751555 @default.
• W2782140699 hasConceptScore W2782140699C2777752497 @default.
• W2782140699 hasConceptScore W2782140699C2780035454 @default.
• W2782140699 hasConceptScore W2782140699C2781357877 @default.
• W2782140699 hasConceptScore W2782140699C55493867 @default.
• W2782140699 hasConceptScore W2782140699C555293320 @default.
• W2782140699 hasConceptScore W2782140699C71924100 @default.
• W2782140699 hasConceptScore W2782140699C98274493 @default.
• W2782140699 hasIssue "1" @default.
• W2782140699 hasLocation W27821406991 @default.
• W2782140699 hasLocation W27821406992 @default.
• W2782140699 hasLocation W27821406993 @default.
• W2782140699 hasLocation W27821406994 @default.
• W2782140699 hasLocation W27821406995 @default.
• W2782140699 hasLocation W27821406996 @default.
• W2782140699 hasOpenAccess W2782140699 @default.
• W2782140699 hasPrimaryLocation W27821406991 @default.
• W2782140699 hasRelatedWork W1570058872 @default.
• W2782140699 hasRelatedWork W1973980078 @default.
• W2782140699 hasRelatedWork W2165875059 @default.
• W2782140699 hasRelatedWork W2353854665 @default.
• W2782140699 hasRelatedWork W2471799847 @default.
• W2782140699 hasRelatedWork W2770031651 @default.
• W2782140699 hasRelatedWork W2783733457 @default.
• W2782140699 hasRelatedWork W2793180802 @default.
• W2782140699 hasRelatedWork W2901576561 @default.
• W2782140699 hasRelatedWork W391090057 @default.
• W2782140699 hasVolume "13" @default.
• W2782140699 isParatext "false" @default.
• W2782140699 isRetracted "false" @default.

• next